Saúl Oswaldo Lugo Reyes

Dr. Saúl Oswaldo Lugo Reyes

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Clinical Immunology
Verified
Journal Article
Closed access
EGEduardo Guaní-Guerra
Eduardo Guaní-Guerra
TSTeresa Santos-Mendoza
Teresa Santos-Mendoza
SRSaúl Oswaldo Lugo Reyes
Saúl Oswaldo Lugo Reyes
LTLuis Manuel Teran
Luis Manuel Teran

17 October 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KRKatrina L. Randall
Katrina L. Randall
SCStephanie S.-Y. Chan
Stephanie S.-Y. Chan
CMCindy S. Ma
Cindy S. Ma
IFIvan Fung
Ivan Fung
YMYan Mei
Yan Mei
CGChristopher C. Goodnow
Christopher C. Goodnow
In humans, DOCK8 immunodeficiency syndrome is characterized by severe cutaneous viral infections. Thus, CD8 T cell function may be compromised in the absence of DOCK8. In this study, by analyzing mutant mice and humans, we demonstrate a critical, intrinsic role for DOCK8 in peripheral CD8 T cell survival and function. DOCK8 mutation selectively diminished the abundance of circulating naive CD8 T cells in both species, and in DOCK8-deficient humans, most CD8 T cells displayed an exhausted CD45RA+CCR7− phenotype. Analyses in mice revealed the CD8 T cell abnormalities to be cell autonomous and primarily postthymic. DOCK8 mutant naive CD8 T cells had a shorter lifespan and, upon encounter with antigen on dendritic cells, exhibited poor LFA-1 synaptic polarization and a delay in the first cell division. Although DOCK8 mutant T cells underwent near-normal primary clonal expansion after primary infection with recombinant influenza virus in vivo, they showed greatly reduced memory cell persistence and recall. These findings highlight a key role for DOCK8 in the survival and function of human and mouse CD8 T cells.

10 June 2021 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
LCLina M. Castano-Jaramillo
Lina M. Castano-Jaramillo
MYMarco Antonio Yamazaki-Nakashimada
Marco Antonio Yamazaki-Nakashimada
POPatricia M. O’fArrill-Romanillos
Patricia M. O’fArrill-Romanillos
DZDavid Muzquiz Zermeño
David Muzquiz Zermeño
SMSelma C. Scheffler Mendoza
Selma C. Scheffler Mendoza
SRSaúl Oswaldo Lugo Reyes
Saúl Oswaldo Lugo Reyes

26 August 2022 in Science Immunology
Verified
Journal Article
Closed access
WRWilliam Rae
William Rae
JSJohn M. Sowerby
John M. Sowerby
DVDorit Verhoeven
Dorit Verhoeven
MYMariam Youssef
Mariam Youssef
PKPrasanti Kotagiri
Prasanti Kotagiri
KSKenneth G. C. Smith
Kenneth G. C. Smith
Tumor necrosis factor receptor–associated factor 3 (TRAF3) is a central regulator of immunity. TRAF3 is often somatically mutated in B cell malignancies, but its role in human immunity is not defined. Here, in five unrelated families, we describe an immune dysregulation syndrome of recurrent bacterial infections, autoimmunity, systemic inflammation, B cell lymphoproliferation, and hypergammaglobulinemia. Affected individuals each had monoallelic mutations in TRAF3 that reduced TRAF3 expression. Immunophenotyping showed that patients’ B cells were dysregulated, exhibiting increased nuclear factor-κB 2 activation, elevated mitochondrial respiration, and heightened inflammatory responses. Patients had mild CD4 + T cell lymphopenia, with a reduced proportion of naïve T cells but increased regulatory T cells and circulating T follicular helper cells. Guided by this clinical phenotype, targeted analyses demonstrated that common genetic variants, which also reduce TRAF3 expression, are associated with an increased risk of B cell malignancies, systemic lupus erythematosus, higher immunoglobulin levels, and bacterial infections in the wider population. Reduced TRAF3 conveys disease risks by driving B cell hyperactivity via intrinsic activation of multiple intracellular proinflammatory pathways and increased mitochondrial respiration, with a likely contribution from dysregulated T cell help. Thus, we define monogenic TRAF3 haploinsufficiency syndrome and demonstrate how common TRAF3 variants affect a range of human diseases.

21 January 2019 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
ABAidé Tamara Staines Boone
Aidé Tamara Staines Boone
ICIvan K. Chinn
Ivan K. Chinn
CACarmen Alaez-Versón
Carmen Alaez-Versón
MYMarco A. Yamazaki-Nakashimada
Marco A. Yamazaki-Nakashimada
KCKarol Carrillo-Sánchez
Karol Carrillo-Sánchez
SRSaúl Oswaldo Lugo Reyes
Saúl Oswaldo Lugo Reyes
DNA repair defects are inborn errors of immunity that result in increased apoptosis and oncogenesis. DNA Ligase 4-deficient patients suffer from a wide range of clinical manifestations since early in life, including: microcephaly, dysmorphic facial features, growth failure, developmental delay, mental retardation; hip dysplasia, and other skeletal malformations; as well as a severe combined immunodeficiency, radiosensitivity, and progressive bone marrow failure; or, they may present later in life with hematological neoplasias that respond catastrophically to chemo- and radiotherapy; or, they could be asymptomatic. We describe the clinical, laboratory, and genetic features of five Mexican patients with LIG4 deficiency, together with a review of 36 other patients available in PubMed Medline. Four out of five of our patients are dead from lymphoma or bone marrow failure, with severe infection and massive bleeding; the fifth patient is asymptomatic despite a persistent CD4+ lymphopenia. Most patients reported in the literature are microcephalic females with growth failure, sinopulmonary infections, hypogammaglobulinemia, very low B-cells, and radiosensitivity; while bone marrow failure and malignancy may develop at a later age. Dysmorphic facial features, congenital hip dysplasia, chronic liver disease, gradual pancytopenia, lymphoma or leukemia, thrombocytopenia, and gastrointestinal bleeding have been reported as well. Most mutations are compound heterozygous, and all of them are hypomorphic, with two common truncating mutations accounting for the majority of patients. Stem-cell transplantation after reduced intensity conditioning regimes may be curative.

28 December 2015 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
SRSaúl Oswaldo Lugo Reyes
Saúl Oswaldo Lugo Reyes
GRGuadalupe Ramirez-Vazquez
Guadalupe Ramirez-Vazquez
AHAlonso Cruz Hernández
Alonso Cruz Hernández
EMEdgar A. Medina-Torres
Edgar A. Medina-Torres
ARAna Belen Ramirez-Lopez
Ana Belen Ramirez-Lopez
CMChiharu Murata
Chiharu Murata